Roche receives FDA approval for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE

/PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced US Food and Drug Administration (FDA) approval of the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay,...

Related Keywords

Germany ,Japan ,United States ,Hilgenbrink ,Nordrhein Westfalen ,France ,Switzerland ,American ,German ,Jo Lynn Garing ,Genentech ,Drug Administration ,Head Of Pathology Lab At Roche Diagnostics ,Journal Of Pharmaceutical Sciences ,Roche Diagnostics Communications ,International Agency For Research On Cancer ,Roche Group ,Society Of Gynecologic Oncology ,American Cancer Society ,Immunogen Inc ,Rxdx Assay ,Jill German ,Pathology Lab ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Rev Clin Oncol ,From Therapeutics ,Gynecologic Oncology ,Cancer Society ,Ovarian Cancer ,Clinical Oncology Clin ,Global Cancer Observatory ,International Agency ,Lynn Garing ,Roche Diagnostics ,Roche ,